(MENAFN- PR Newswire)
SAN DIEGO, Nov. 27, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ("Halozyme") today announced that members of the executive leadership team are scheduled to present and host investor meetings at the following investor conferences.
Details on the presentations are as follows:
| Event: |
|
|
|
Piper Sandler 36th Annual Healthcare Conference |
| Presenter: |
|
|
|
Nicole LaBrosse, Chief Financial Officer |
| Format: |
|
|
|
Fireside Chat and 1x1 Meetings |
| Presentation Date: |
|
|
|
Wednesday, December 4, 2024 |
| Presentation Time: |
|
|
|
10:30am PT / 1:30pm ET |
| Location: |
|
|
|
New York, NY |
|
|
|
|
|
| Event: |
|
|
|
7th Annual Evercore ISI HealthCONx Conference |
| Presenter: |
|
|
|
Helen Torley, President and Chief Executive Officer |
| Format: |
|
|
|
Fireside Chat and 1x1 Meetings |
| Presentation Date: |
|
|
|
Wednesday, December 4, 2024 |
| Presentation Time: |
|
|
|
9:30am PT / 12:30pm ET |
| Location: |
|
|
|
Miami, FL |
|
|
|
|
|
A live audio webcast of the presentations will be available in the
Investor Relations section
of the Company's website. Replays of the audio webcasts will be available for 90 days following the conference.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched more than 800,000 patient lives in post-marketing use in eight commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.
For more information visit and connect with us on LinkedIn and Twitter.
Contacts:
Tram
Bui
VP, Investor Relations and Corporate Communications
609-359-3016
[email protected]
Samantha Gaspar
Teneo
212-886-9356
[email protected]
SOURCE Halozyme Therapeutics, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
GET STARTED
MENAFN27112024003732001241ID1108932326
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.